top of page
検索

Terrapeutics Pharma Partners with HekaBio K.K. to Bring Revolutionary Drug Discovery Platform to Japan




Jerusalem, Israel, and Tokyo, Japan – June 19, 2024

Terrapeutics Pharma Ltd. (“Terrapeutics”), a trailblazing drug discovery company specializing in identifying novel drugs from soil-based bacteria, today announced a strategic partnership with HekaBio K.K. (“HekaBio”), a leading Japan-based healthcare innovation in-licensing and commercialization platform.


Terrapeutics revolutionizes drug discovery by targeting soil communities based on specific human drug targets. This innovative method compels soil bacteria to utilize their ‘Natural Intelligence’ to produce highly specific small-molecule inhibitors. By identifying these organisms and their biosynthetic clusters, Terrapeutics unveils nature's hidden molecules, increasing access by an astounding 1,000-fold compared to conventional methods.


The announced collaboration aims to introduce Terrapeutics' innovative drug discovery platform to the Japanese market, focusing on attracting pharmaceutical companies to collaborate on discovering novel therapeutics targeting previously ‘undruggable’ targets. Terrapeutics’ platform grants Japanese Pharma swift access to drug-target-specific natural molecules, enabling rapid identification of natural inhibitors for the most challenging drug targets. These natural solutions can revolutionize drug discovery by serving as direct treatments or inspiring biomimicry approaches.


As part of this partnership, Rob Claar, CEO of HekaBio, will join Terrapeutics’ Advisory Board. He will bring his extensive experience and deep knowledge of the Japanese biopharma sector to support the company’s vision for Japan. Terrapeutics will leverage HekaBio’s extensive network and market expertise to facilitate integrating and adopting its innovative drug discovery platform within Japan’s pharmaceutical industry.


“We are excited to partner with HekaBio to introduce our revolutionary drug discovery platform to Japan,” said Eddie Sadan, CEO and Co-Founder of Terrapeutics. “Adding Rob Claar to our Advisory Board is a significant milestone for Terrapeutics. His thought leadership and expertise will be instrumental in fostering collaborations with Japanese pharmaceutical companies, enabling us to discover novel therapeutics from soil-based bacteria and address unmet medical needs.”


Rob Claar, CEO and Co-Founder of HekaBio added, “This partnership allows us to bring an innovative tool to Japan’s pharmaceutical landscape, enhancing our mission to accelerate access to global innovations. We look forward to working closely with Terrapeutics to unlock new therapeutic possibilities and drive advancements in drug discovery.”


About HekaBio:

HekaBio is a leading Japan-based MedTech and therapeutics in-licensing and commercialization platform. Its mission is empowering patients through accelerated access to global healthcare innovations, which it achieves through its core values of Collaboration, Creativity and Commitment.


About Terrapeutics Pharma:

Terrapeutics is a drug discovery company that revives the lost art of discovering novel therapeutic solutions from soil-based microorganisms. Its groundbreaking discovery technology combines synthetic biology, sequencing tools, and computational biology to harness soil's full potential, enabling the discovery of novel small molecules that can tackle 'undruggable' targets.



Terrapeutics Pharma Contact:

Eddie Sadan, CEO

  

Contact HekaBio from here

Mari Tanaka, Corporate Communications


Comments


bottom of page